Line 94: | Line 94: | ||
− | <h2><a href="https://2018.igem.org/Team:Bielefeld-CeBiTec/ | + | <h2><a href="https://2018.igem.org/Team:Bielefeld-CeBiTec/Toxicity_Results">Toxicity</a></h2> |
<article> | <article> | ||
Line 101: | Line 101: | ||
− | <h2><a href="https://2018.igem.org/Team:Bielefeld-CeBiTec/ | + | <h2><a href="https://2018.igem.org/Team:Bielefeld-CeBiTec/Accumulation_Results">Accumulation</a></h2> |
<article> | <article> | ||
Line 108: | Line 108: | ||
− | <h2><a href="https://2018.igem.org/Team:Bielefeld-CeBiTec/ | + | <h2><a href="https://2018.igem.org/Team:Bielefeld-CeBiTec/siRNA_Results">Silencing</a></h2> |
<article> | <article> | ||
Line 116: | Line 116: | ||
− | <h2><a href="https://2018.igem.org/Team:Bielefeld-CeBiTec/ | + | <h2><a href="https://2018.igem.org/Team:Bielefeld-CeBiTec/Ferritin_Results">Nanoparticles</a></h2> |
<article> | <article> | ||
− | We were able to enhance iron nanoparticle formation by overexpressing ferritin in <i>Escherichia coli</i>. Furthermore, we were able to use a | + | We were able to enhance iron nanoparticle formation by overexpressing ferritin in <i>Escherichia coli</i>. Furthermore, we were able to use a mutated variant of the human ferritin to produce gold an silver nanoparticles. |
</article> | </article> | ||
Revision as of 23:03, 17 October 2018
Results Overview